New hope for pancreatic cancer patients: drug combo trial before surgery
NCT ID NCT05209074
Summary
This early-stage study is testing whether adding the drug ivosidenib to standard chemotherapy (mFOLFIRINOX) before surgery helps people with operable pancreatic cancer. The goal is to see if this combination is safe and effective at shrinking tumors before surgical removal. Researchers will enroll 16 participants to find the best dose and see how well the treatment works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
Conditions
Explore the condition pages connected to this study.